Eli Lilly didn’t just dip a toe into the psychedelic pool. On July 16, 206, it dove in headfirst, agreeing to buy Atai-Beckley for up to $380000000.
The deal? $280000000 cash up front. Another $100000000 in contingent value rights tied to milestones. The prize? BPL-003. This is mebufotenin benzoate. It’s a fast-acting, DMT-derived nasal spray currently in Phase 3 trials for treatment-resistant depression.
Let’s be clear about what this signals. This is the biggest transaction the psychedelic sector has ever seen.
Just eleven months earlier, AbbVie had paid up to $120000000 for Gilgamesh Pharmaceuticals. Gilgamesh’s star asset, Bretisilocin (GM2505), is a 5-HT2A receptor agonist. It causes hallucinations and psychedelic effects that last between 60 and 90 minutes.
Two deals. Two different molecules. One clear trend.
Psychedelic psychiatry isn’t a biotech novelty anymore. It’s a sector where the world’s largest pharmaceutical companies are writing nine-and-ten-figure checks.
The Commercial Proof That Changed Everything
You need to understand Spravato.
Johnson & Johnson’s esketamine nasal spray has quietly become the blueprint for the entire industry. It’s a Schedule III drug. It’s ketamine-derived. It’s “psychedelic-adjacent,” in the polite sense.
Annual sales are hovering close to $2000000000 Major Depressive Disorder (MDD) and depression with suicidal ideation have a viable treatment now.
Spravato proved something critical. A dissociative-acting molecule, given under clinical supervision, can clear FDA approval. It can secure durable reimbursement. It can become a commercial franchise instead of a boutique therapy.
Every pharma business-development team in the country saw that revenue number. They saw the template. And they realized they couldn’t afford to stay on the sidelines.
The Regulatory Tailwind Is Real
Government policy shifted sharply in April 2026 President Trump issued an executive order directing federal agencies to accelerate reviews of psychedelic therapies.
The FDA responded within a week.
Three psychedelic programs received National Priority Vouchers. Standard review times of 10 to 12 months compressed to 1 or 2 months.
Compass Pathways is moving fast on the back of this momentum.
COMP360 is their synthetic psilocybin candidate. It posted positive Phase 3 results in mid-2025 (COMP005) and early 2026 (COMP006). The later trial showed durability lasting up to six months.
Compass is already filing a rolling New Drug Application (NDA). Completion is targeted for Q4 2026. A US launch could hit in H1 2027. If that happens, COMP360 becomes the first “classic” psychedelic approved for a psychiatric indication in the United States.
Where Definux Fits In The Hierarchy
Definium Therapeutics isn’t playing catch-up. It’s setting a high bar for efficacy.
In June 2026, they reported results from the Phase 3 Emerge trial. A single 100-microgram oral dose of DT120—a lysergide derivative (LSD)—produced an 8.1-point improvement on the MADRS scale at six weeks compared to placebo.
The effect held at twelve weeks.
Analysts at Jefferies called those results “profound.” Cross-trial comparisons suggest DT120 may outperform approved antidepressants, Spravato, and Compass’s psilocybin data. Note that cross-trial comparisons should always be read cautiously. Trial designs differ. Variables aren’t identical. But the magnitude of effect is notable.
Dr. Dan Karlin, Chief Medical Officer at Definium, put it bluntly.
“The standard of care is failing patients,” Karlin said. “Over 50 million adults in the US live with GAD and MDD. They wait weeks to see if a pill works. Many experience partial response or persistent side effects.”
Definium is trying to fix that broken model.
DT120 ODT (orally dissolving tablet) is designed to address the underlying cause of the disease. Not just mask symptoms. Karlin pointed to a broader Phase 3 slate: Ascend, Voyage, Panorama, and a new Haven trial for PTSD.
The goal? A versatile solution across common mental health disorders.
Does The Spravato Model Scale?
Yes. But not like a pill.
Every serious late-stage candidate—BPL-003, COMP0360, DT122—is built for in-clinic administration. Monitored. Single or limited dose. Paired with psychological support.
This isn’t a pharmacy-dispensed drug.
It’s an intervention.
Each dosing session requires a clinician. A monitored space. Hours of patient time. Volume doesn’t scale linearly. You can’t just manufacture more pills and ship them.
Spravato’s growth curve proves this model works. It scales like infusion therapy or interventional psychiatry. It becomes a multibillion-dollar franchise.
The bottleneck isn’t demand. It’s infrastructure.
We need more clinics. More trained prescribers. More treatment bays. This constraint has shaped Spravato’s rollout for six years. It will shape every psychedelic entry for the next decade.
Who Is Left On The Table?
The landscape is consolidating.
AtaiBeckley is now owned by Lilly. BPL-003 targets TRD. Phase 3 readouts aren’t expected until 2029. Lilly is betting on a “class effect,” using data from J&J and Compass to de-risk a still-unproven asset. CEO Srinivas Rao describes the pipeline as a “differentiated and diversified” suite of next-gen therapies. Beyond BPL-003, they have VLS-01 (an oral DMT film) and EMP-01 (oral R-MDMA for social anxiety).
Compass Pathways is the regulatory front-runner. If FDA and DEA cooperate, 2027 is the target. It’s arguably the most obvious independent acquisition target. A large-cap player wanting a first-mover psilocyben franchise would snap this up. Wall Street expects a deal before or shortly after FDA approval, likely late 2026 or early2027.
Definium Therapeutics is running three separate Phase 3 trials. Strong efficacy data. Partnered with Catalent for formulation. A plausible target for a company that missed the big Lilly or AbbVie moves.
Gilgamesh is already absorbed. Sold to AbbVie. It set the precedent for monetizing a single asset rather than building full commercial infrastructure.
Johnson & Johnson is the incumbent. Spravato is the benchmark. Everyone is measured against J&J.
The Scheduling Trap
Here is the catch the Spravato comparison often ignores.
Ketamine and Esketamine aren’t “classic” psychedelics under the Controlled SubstancesAct (CSA) in the same way psilocybin or LSD are.
Even if COMP360 or DT-20 clears FDA approval, rescheduling with the DEA is a separate, sequential step.
Compass has stated their 2027 launch is contingent on rescheduling. That adds a second regulatory gate. Large-pharma acquirers have to underwriting this variable alongside clinical and commercial risk.
This is why the April 2026 executive orders mattered so much. The federal apparatus governing approval and scheduling is now aligned. That policy risk reduction is what makes a $3800000 investment committee comfortable.
The Market Is Here
The data was already doing the work. Compass and Definium had the efficacy signals. What Lilly’s move confirms is that the commercial and regulatory risk has finally fallen low enough for a balance sheet of this size to cover it.
Bloomberg Intelligence estimates the psychedelic treatment market will hit roughly $70000000 billion in sales by2032.
That number looked fanciful five years ago. Psychedelics were federally scheduled curiosities then. Zero institutional capital.
The field won’t scale like a blockbuster oral drug. It will scale like Spravato did. Clinic by clinic. Prescriber by prescriber.
But now there’s a growing list of billion-dollar buyers willing to fund the buildout.
The inflection point isn’t coming. It’s already here.
